Livzon Pharmaceutical Group Inc. (SHE:000513)
China flag China · Delayed Price · Currency is CNY
31.70
-0.28 (-0.88%)
Nov 17, 2026, 3:05 PM CST

SHE:000513 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Cash & Equivalents
7,2509,30510,82711,32610,4119,146
Short-Term Investments
373.78270.56----
Trading Asset Securities
67.221,34589.3681.79108.09182.77
Cash & Short-Term Investments
7,69110,92110,91711,40810,5199,329
Cash Growth
-30.36%0.04%-4.30%8.44%12.76%-6.52%
Accounts Receivable
2,4623,3863,2493,5754,0393,294
Other Receivables
81.7790.7859.2851.9131.3264.37
Receivables
2,5443,4773,3083,6274,0713,358
Inventory
1,7781,5611,9982,0612,0451,663
Other Current Assets
465.84159.53197.44171.11352322.42
Total Current Assets
12,48016,11816,42017,26616,98714,673
Property, Plant & Equipment
4,6044,3224,5374,5664,5924,239
Long-Term Investments
3,4651,9162,0851,6701,7381,695
Goodwill
1,095124.91124.91124.91103.04103.04
Other Intangible Assets
451.27468.85403.68426.28557.44260.28
Long-Term Deferred Tax Assets
447.09427.72356.35301.92283.89252.69
Long-Term Deferred Charges
575.69524.74396.25468.62416.74704.41
Other Long-Term Assets
128.4984.09132.55221.17189.66444.62
Total Assets
23,24623,98524,45625,04524,86822,372

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Accounts Payable
1,3221,3181,5841,6581,8621,817
Accrued Expenses
251.713,2413,1093,2953,2492,656
Short-Term Debt
3,1592,1202,4551,8601,6222,043
Current Portion of Long-Term Debt
-157.8936.21647.47--
Current Portion of Leases
16.6615.3312.5312.210.449.28
Current Income Taxes Payable
176.0982.43112.88181.5892.5797.45
Current Unearned Revenue
60.49104.38124.63138226.19167.8
Other Current Liabilities
3,419180.71191.27294.49334.42134.34
Total Current Liabilities
8,4057,2207,6258,0877,3976,925
Long-Term Debt
185.8749.361,4661,6131,974636.78
Long-Term Leases
2317.3213.19.0311.615.27
Long-Term Unearned Revenue
244.71242.16238.42269.37273.21258.88
Long-Term Deferred Tax Liabilities
243.09210.28207.39209.81191.96156.89
Other Long-Term Liabilities
5.5-0.5-908478
Total Liabilities
9,1078,4389,55010,2789,9328,061

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Common Stock
887.91887.91911.35923.94935.55937.87
Additional Paid-In Capital
--257.851,3221,4221,629
Retained Earnings
11,85112,73812,50611,65311,18210,461
Treasury Stock
---196.62--55.94-71.21
Comprehensive Income & Other
280.33262.25383.57143.07391.6446.55
Total Common Equity
13,01913,88813,86214,04213,87613,004
Minority Interest
1,1201,6591,043724.211,0601,307
Shareholders' Equity
14,13915,54714,90614,76714,93614,311
Total Liabilities & Equity
23,24623,98524,45625,04524,86822,372

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Total Debt
3,3843,0603,9834,1413,6192,694
Net Cash (Debt)
4,3077,8616,9347,2666,9016,635
Net Cash Growth
-39.57%13.37%-4.57%5.29%4.01%-17.58%
Net Cash Per Share
4.858.807.537.817.377.09
Filing Date Shares Outstanding
887.91887.91908.91923.94932.23929.97
Total Common Shares Outstanding
887.91887.91908.91923.94932.23929.97
Working Capital
4,0758,8988,7959,1799,5917,748
Book Value Per Share
14.6615.6415.2515.2014.8813.98
Tangible Book Value
11,47313,29513,33413,49113,21612,640
Tangible Book Value Per Share
12.9214.9714.6714.6014.1813.59
Buildings
---3,745-3,123
Machinery
-8,9868,7294,5517,5773,764
Construction In Progress
-234.18257.37289.31602.44554.58